Illumina, Inc. (NASDAQ:ILMN) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Illumina, Inc. (NASDAQ:ILMNGet Rating) have been given an average rating of “Hold” by the fourteen analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $421.91.

A number of equities research analysts recently issued reports on the company. Bank of America raised Illumina from an “underperform” rating to a “neutral” rating and set a $390.00 price target for the company in a research note on Friday, January 7th. OTR Global upgraded Illumina from a “mixed” rating to a “positive” rating in a report on Tuesday, March 29th. SVB Leerink cut their price target on Illumina from $430.00 to $400.00 and set a “market perform” rating on the stock in a report on Friday, February 11th. Barclays upgraded Illumina from an “underweight” rating to an “equal weight” rating and cut their price target for the company from $432.72 to $412.00 in a report on Tuesday, January 11th. Finally, StockNews.com started coverage on Illumina in a report on Thursday, March 31st. They issued a “hold” rating on the stock.

Shares of NASDAQ:ILMN traded down $7.82 during trading on Tuesday, hitting $311.28. The company had a trading volume of 2,207 shares, compared to its average volume of 933,492. The stock has a market cap of $48.90 billion, a price-to-earnings ratio of 61.64, a price-to-earnings-growth ratio of 2.60 and a beta of 0.94. Illumina has a one year low of $302.79 and a one year high of $526.00. The company has a fifty day simple moving average of $335.58 and a two-hundred day simple moving average of $364.73. The company has a debt-to-equity ratio of 0.16, a current ratio of 2.48 and a quick ratio of 2.09.

Illumina (NASDAQ:ILMNGet Rating) last issued its quarterly earnings results on Thursday, February 10th. The life sciences company reported $0.75 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.25. Illumina had a return on equity of 11.35% and a net margin of 16.82%. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same period last year, the company earned $1.22 EPS. Illumina’s quarterly revenue was up 25.2% compared to the same quarter last year. On average, equities research analysts anticipate that Illumina will post 4.14 earnings per share for the current year.

In other news, SVP Aimee L. Hoyt sold 2,474 shares of the business’s stock in a transaction dated Tuesday, April 12th. The stock was sold at an average price of $350.51, for a total value of $867,161.74. Following the completion of the transaction, the senior vice president now owns 5,342 shares of the company’s stock, valued at approximately $1,872,424.42. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Phillip G. Febbo sold 1,988 shares of Illumina stock in a transaction dated Wednesday, April 6th. The shares were sold at an average price of $360.01, for a total value of $715,699.88. Following the completion of the transaction, the senior vice president now owns 5,774 shares of the company’s stock, valued at approximately $2,078,697.74. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,830 shares of company stock valued at $1,709,023. 0.23% of the stock is currently owned by insiders.

Several institutional investors have recently made changes to their positions in the stock. Keybank National Association OH increased its stake in shares of Illumina by 0.7% in the 3rd quarter. Keybank National Association OH now owns 3,783 shares of the life sciences company’s stock valued at $1,534,000 after purchasing an additional 28 shares in the last quarter. Patten Group Inc. increased its stake in Illumina by 0.9% during the 4th quarter. Patten Group Inc. now owns 3,082 shares of the life sciences company’s stock worth $1,173,000 after buying an additional 29 shares in the last quarter. EFG Asset Management Americas Corp. increased its stake in Illumina by 2.2% during the 4th quarter. EFG Asset Management Americas Corp. now owns 1,372 shares of the life sciences company’s stock worth $522,000 after buying an additional 29 shares in the last quarter. Corient Capital Partners LLC increased its stake in Illumina by 1.7% during the 3rd quarter. Corient Capital Partners LLC now owns 1,808 shares of the life sciences company’s stock worth $733,000 after buying an additional 30 shares in the last quarter. Finally, MML Investors Services LLC increased its stake in Illumina by 0.8% during the 3rd quarter. MML Investors Services LLC now owns 3,898 shares of the life sciences company’s stock worth $1,581,000 after buying an additional 30 shares in the last quarter. Hedge funds and other institutional investors own 85.41% of the company’s stock.

Illumina Company Profile (Get Rating)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

Featured Articles

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.